Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Highlights • Quavonlimab, a novel anti–CTLA-4 antibody, in combination with pembrolizumab was investigated in a first-in-human study. • The combination therapy was safe and tolerable and showed antitumor activity in patients with advanced NSCLC. • Data from this study led to a recommended phase II dose of 25 mg Q6W for quavonlimab when used with pembrolizumab.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.